IL6 and inflammatory bowel disease: Moreover, IBD patients with a reduction in IL-6 from baseline to 10 weeks receiving biologic therapy have shown to be a 4.7-fold higher probability of achieving a clinical response at 12 months compared to those without IL-6 reduction (38).